Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2011-09-15 14:10:44
Reporting Period:
Filing Date:
Accepted Time:
2011-09-15 14:10:44
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
926617 Vermillion Inc. VRML In Vitro & In Vivo Diagnostic Substances (2835) 330595156
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1502237 Ashish Kohli C/o Vermillion, Inc. 12117 Bee Caves Rd
Building Three, Suite 100
Austin TX 78738
Vp Of Corporate Strategy No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-09-15 200 $2.99 11,700 No 4 P Direct
Common Stock Acquisiton 2011-09-15 1,800 $3.01 13,500 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
  1. The two purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 14, 2011.